Daraxonrasib
The first drug that blocks all active RAS variants, approved by the FDA in August 2026 for metastatic pancreatic cancer, where KRAS drives 90% of tumours.
Daraxonrasib is Revolution Medicines' tri-complex inhibitor. Phase 1/2: median OS ~14.5 months in second-line pancreatic cancer versus historical ~6 months. RASolute 302 (second-line PDAC) supported FDA approval on 26 August 2026 as Rasonque for metastatic pancreatic cancer; RASolute 303 (first-line) and the NSCLC phase 3 (RASolve 301) continue. Rash and stomatitis are the main toxicities.
1.Drug binds cyclophilin A inside the cell
- Route
- Oral
- Schedule
- 300 mg once daily (phase 3 dose; 200 mg in some cohorts)
- Dose modifications
- Reduce for grade 3 rash or stomatitis
- Monitoring
- Skin, oral mucosa, LFTs
Source: clinicaltrials.gov/study/NCT06625320. Doses are for orientation; the current label governs.
- Notes
- No UK marketing authorisation as of September 2026, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
- NHS England
- Not routinely funded
Sources: NICE search: daraxonrasib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
- Jun 2024DesignationUS
Breakthrough Therapy designation, previously treated metastatic PDAC source
- Dec 2025Filing / dealUS
RASolute 302 phase 3 fully enrolled; topline 2026 source
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2026 | Metastatic pancreatic cancer (previously treated) — Rasonque, 26 August 2026 |
| Adverse event |
|---|
| Rash |
| Stomatitis |
| Nausea |
| Diarrhoea |
| Fatigue |
Most common; mostly grade 1-2 per phase 1/2 reports. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational; NDA expected after RASolute 302 | not disclosed | — |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Daraxonrasib" OR ABSTRACT:"Daraxonrasib" OR TITLE:"Rasonque" OR ABSTRACT:"Rasonque" OR TITLE:"RMC-6236" OR ABSTRACT:"RMC-6236") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Daraxonrasib, not a curated reading list.